Atopic Dermatitis Clinical Trials in Birmingham, Alabama
12 recruitingBirmingham, Alabama
Showing 1–12 of 12 trials
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Atopic Dermatitis
Sanofi1,000 enrolled43 locationsNCT07290803
Recruiting
Phase 2
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled17 locationsNCT07298395
Recruiting
Phase 4
A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Atopic Dermatitis
Eli Lilly and Company200 enrolled66 locationsNCT07006792
Recruiting
Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 3
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Phase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Atopic Dermatitis
Pfizer500 enrolled31 locationsNCT06807281
Recruiting
Phase 3
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
LEO Pharma195 enrolled72 locationsNCT06311682
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Atopic Dermatitis
Galderma R&D1,000 enrolled108 locationsNCT06988605
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled97 locationsNCT05995964
Recruiting
Phase 2
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
Novartis Pharmaceuticals224 enrolled99 locationsNCT06947993
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Atopic Dermatitis
Incyte Corporation240 enrolled96 locationsNCT06832618